p1np (bone formation) Search Results


bone formation marker procollagen type i n terminal propeptide p1np  (Sangon Biotech)
86
Sangon Biotech bone formation marker procollagen type i n terminal propeptide p1np
Upregulation of mammalian Sterile 20-like kinase 4 (MST4) expression in peripheral blood mononuclear cells of clinical osteoporosis patients (OP). (A) Quantitative real-time polymerase chain reaction (RT-qPCR) detection of MST4 mRNA levels in peripheral blood mononuclear cells of OP and healthy controls (Control) ( n = 6). (B, C) Western blot analysis of MST4 protein expression levels (B) and corresponding statistics (C) in OP and Control ( n = 6). (D) Bone mineral density (BMD) levels in OP and Control. (E, F) Expression levels of bone formation markers osteocalcin (OC) (E) and <t>procollagen</t> type I N -terminal propeptide <t>(P1NP)</t> (F) in OP and Control. (G, H) Expression levels of bone formation markers β-CrossLaps (β-CTX) and tartrate-resistant acid phosphatase 5b (TRAcP 5b) in OP and Control. (I) Receiver operating characteristic (ROC) curve analysis of MST4 expression for predicting fragility fractures in OP ( n = 60). ∗ P < 0.05 compared between groups, n = 60 per group（OP 60，Control 60); ns: not significant.
Bone Formation Marker Procollagen Type I N Terminal Propeptide P1np, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p1np+(bone+formation)/bone+formation+i+marker+n+p1np+procollagen+propeptide+terminal+type/pmc13049931-47-9-20
Average 86 stars, based on 1 article reviews
bone formation marker procollagen type i n terminal propeptide p1np - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Upregulation of mammalian Sterile 20-like kinase 4 (MST4) expression in peripheral blood mononuclear cells of clinical osteoporosis patients (OP). (A) Quantitative real-time polymerase chain reaction (RT-qPCR) detection of MST4 mRNA levels in peripheral blood mononuclear cells of OP and healthy controls (Control) ( n = 6). (B, C) Western blot analysis of MST4 protein expression levels (B) and corresponding statistics (C) in OP and Control ( n = 6). (D) Bone mineral density (BMD) levels in OP and Control. (E, F) Expression levels of bone formation markers osteocalcin (OC) (E) and procollagen type I N -terminal propeptide (P1NP) (F) in OP and Control. (G, H) Expression levels of bone formation markers β-CrossLaps (β-CTX) and tartrate-resistant acid phosphatase 5b (TRAcP 5b) in OP and Control. (I) Receiver operating characteristic (ROC) curve analysis of MST4 expression for predicting fragility fractures in OP ( n = 60). ∗ P < 0.05 compared between groups, n = 60 per group（OP 60，Control 60); ns: not significant.

Journal: Journal of Pharmaceutical Analysis

Article Title: MST4 as a key driver of osteoclast activation in osteoporosis

doi: 10.1016/j.jpha.2025.101401

Figure Lengend Snippet: Upregulation of mammalian Sterile 20-like kinase 4 (MST4) expression in peripheral blood mononuclear cells of clinical osteoporosis patients (OP). (A) Quantitative real-time polymerase chain reaction (RT-qPCR) detection of MST4 mRNA levels in peripheral blood mononuclear cells of OP and healthy controls (Control) ( n = 6). (B, C) Western blot analysis of MST4 protein expression levels (B) and corresponding statistics (C) in OP and Control ( n = 6). (D) Bone mineral density (BMD) levels in OP and Control. (E, F) Expression levels of bone formation markers osteocalcin (OC) (E) and procollagen type I N -terminal propeptide (P1NP) (F) in OP and Control. (G, H) Expression levels of bone formation markers β-CrossLaps (β-CTX) and tartrate-resistant acid phosphatase 5b (TRAcP 5b) in OP and Control. (I) Receiver operating characteristic (ROC) curve analysis of MST4 expression for predicting fragility fractures in OP ( n = 60). ∗ P < 0.05 compared between groups, n = 60 per group（OP 60，Control 60); ns: not significant.

Article Snippet: Bone metabolism markers in peripheral blood, such as the bone formation marker procollagen type I N -terminal propeptide (P1NP) (D711084-0048; Sangon Biotech Co., Ltd., Shanghai, China), osteocalcin (OC) (D711187-0048; Sangon Biotech Co., Ltd., Shanghai, China), and bone resorption markers like β-CrossLaps (β-CTX) (D711348; Sangon Biotech Co., Ltd., Shanghai, China), and tartrate-resistant acid phosphatase 5b (TRAcP 5b) (P0332; Beyotime Biotechnology, Shanghai, China), were measured using enzyme-linked immunosorbent assay (ELISA).

Techniques: Sterility, Expressing, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Control, Western Blot